Today, Arrowhead Pharmaceuticals (ARWR) stock is trading at $20.12, which represents ~42.7% growth from yesterday’s close of $14.10. Arrowhead Pharmaceuticals also hit its 52-week high of $22.39 today.
On September 5, Arrowhead Pharmaceuticals stock closed at $14.10—a 432.0% increase from its 52-week low of $2.65 on September 14, 2017.
Why ARWR’s stock price spiked
Today, Arrowhead Pharmaceuticals presented the preliminary clinical data for ARO-HBV at the 18th World Gastroenterology Summit in Auckland, New Zealand. ARO-HBV is an investigational RNA interference therapy with the potential to cure individuals with chronic hepatitis B virus infection.
Arrowhead Pharmaceuticals presented clinical data from two groups in the clinical trial with respect to the 100mg ARO-HBV cohort and the 200mg ARO-HBV cohort. Arrowhead Pharmaceuticals noted that preliminary data from the clinical trial demonstrated that ARO-HBV therapy led to a significant decline in the circulating HBV surface antigen. The company added that ARO-HBV was well-tolerated in individuals with HBV infection.
The data from this clinical trial delivers the first clinical data of Arrowhead Pharmaceuticals’ proprietary Targeted RNAi Molecules (or TRiM). To learn more about the clinical trial data, please refer to the company’s September 6 press release.
Of the six analysts tracking Arrowhead Pharmaceuticals (ARWR) stock in September, two recommended a “strong buy.” Three analysts recommended a “buy,” and one analyst recommended a “hold.”
On September 6, Arrowhead Pharmaceuticals had a consensus 12-month target price of $16.25, which represents an ~19.41% decline over the next 12 months.
On September 6, Arbutus Biopharma had a consensus 12-month target price of $10.79, which represents an ~2.27% return on investment over the next 12 months.
On September 6, Ionis Pharmaceuticals had a consensus 12-month target price of $57.27, which represents an ~30.22% return on investment over the next 12 months.